NCT05589610 - Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

March 26, 2024

Study Completion Date

April 30, 2024

Conditions

Alopecia AreataAlopeciaAlopecia TotalisAlopecia Universalis

Interventions

DRUG

EQ101

EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses

Trial Locations (5)

Sinclair Dermatology, East Melbourne

Fremantle Dermatology, Fremantle

Premier Specialists, Kogarah

Veracity Clinical Research, Woolloongabba

Optimal Clinical Trials Limited, Auckland